|
|
|
Stem Cell Related Patent Number US7112653
| Title: | Composition and method for preserving progenitor cells | | Inventors: | Moore, Jeffrey G.; Kennebunkport, ME, USA | | Summary: | This invention introduces a novel pharmaceutical composition comprised of a carrier and a mannose-binding protein, such that the pylartin protein material is effective in preserving progenitor cells such as hematopoietic progenitor cells. The protein itself is described as having an amino acid sequence comprising AQSLSFSFTKFD (SEQ ID NO:1) and a molecular weight of approximately 12-20 kD, or alternately an amino acid sequence comprising VVAVEFD (SEQ ID NO:3) and a molecular weight of approximately 15-20 kD. Further described are heterodimers and multimers of the protein, as are methods of preserving progenitor cells in vitro, in vivo and ex vivo. Methods are included such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated via the specified protein. Other therapeutic utilities are also enabled such as the expansion of progenitor cell populations ex vivo which increase the success of engraftation, transportation and storage of progenitor cells. Further detailed are the properties of a mannose-binding protein which is a lectin comprising a heterodimer of a first polypeptide and a second polypeptide, wherein the lectin can be obtained from a legume selected from the group consisting of Phaseolus vulgaris, Dolichos lab lab, and Vigna senensis. Therapeutic applications are provided such as in the facilitation of gene therapy in the treatment and cure of a broad range of life-threatening hematologic diseases, such as in hematopoietic therapies in cancer treatment. | | Abstract: | The invention relates to a protein material which is effective to preserve progenitor cells, such as hematopoietic progenitor cells. The protein has an amino acid sequence comprising AQSLSFSFTKFD (SEQ ID NO:1) and a molecular weight of about 12–20 kD, or has an amino acid sequence comprising VVAVEFD (SEQ ID NO:3) and a molecular weight of about 15–20 kD. Heterodimers of the protein are described, and multimers thereof. Methods of using the protein of the invention for preserving progenitor cells in vitro, ex vivo, and in vivo are also described. The invention, therefore, include methods such as myeloablation therapies for cancer treatment wherein myeloid reconstitution is facilitated by means of the specified protein. Other therapeutic utilities are also enabled through the invention, for example, expanding progenitor cell populations ex vivo to increase chances of engraftation, improving conditions for transporting and storing progenitor cells, and facilitated gene therapy to treat and cure a broad range of life-threatening hematologic diseases. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US7112653 | | Application Number: | US2003000737180 | | Date Filed: | 15/12/2003 | | Date Published: | 26/09/2006 | | Assignee: | Inclone Systems, Incorporated, New York, NY, USA |
|
|
